Eupraxia Pharmaceuticals Inc. EPRX
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- -10.46%
- 1 year
- +24.04%
- Market cap
- 446.66M
- EPS (ttm)
- -1.02
- Shares out
- 35.62M
- YTD return
- -10.46%
- 1-year return
- +24.04%
- Volume
- 660.27K
- Avg volume
- 643.82K
- Open
- 7.04
- Previous close
- 6.88
- Day's range
- 6.60 – 7.01
- 52-week range
- 5.25 – 9.32
- Beta
- 1.23
1M -0.94 (-12.14%)
Key statistics
- Enterprise value
- 92.53M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 38.15
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -14.62M
- Total cash
- 23.32M
- Total debt
- 4.66M
- Return on equity
- -314.41%
- Short % of float
- 0.00%
- 50-day average
- 3.00
- 200-day average
- 2.78
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | Rodman & Renshaw | init | — | Buy |
About Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- eupraxiapharma.com
News
Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day 
Eupraxia Reaches Its Target Enrollment Of 120 Patients In Phase 2b Placebo-Controlled Blinded Portion Of RESOLVE Trial 
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis 
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences 
HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $11 Price Target 
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis 
Wedbush Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17 
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences 
12 Health Care Stocks Moving In Wednesday's After-Market Session 
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
Your note
Sign in to keep a note on EPRX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Scotia Capital Inc. | 3.92% | 1,396,281 | 4.31M | Sep 29, 2024 |
| Royal Bank of Canada | 0.76% | 271,287 | 838.28K | Sep 29, 2024 |
| Bank of Montreal /CAN/ | 0.14% | 49,250 | 152.18K | Sep 29, 2024 |
| Goldman Sachs Group Inc | 0.10% | 34,500 | 106.60K | Sep 29, 2024 |
| UBS Group AG | 0.09% | 33,000 | 101.97K | Sep 29, 2024 |
| 180 Wealth Advisors, LLC | 0.04% | 13,000 | 40.17K | Sep 29, 2024 |